Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

LON/0QCV stock hub

LON/0QCV has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0QCVis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

261.3B

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0QCV

In the news

Latest news · LON/0QCV

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E13.5

P25 12.9P50 16.9P75 23.5

Trailing P/E96

P25 15.9P50 22.9P75 35.8

ROEn/a

P25 -54.2P50 2.1P75 13.7

ROIC22.2

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0QCV market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

212

Groups with data

Currency

USD

Showing 212 of 212 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	57,000
Employees Change	5,000%
Employees Change Percent	10
Enterprise value	$308B
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	US00287Y1091
Last refreshed	2026-05-10
Market cap	$261.3B
Price	$201
Price currency	USD
Rev Per Employee	834,616.54x
Sector	Healthcare
Sic	2836
Symbol	lon/0QCV
Website	https://www.abbvie.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.04%
EV Earnings	113.12x
EV/EBIT	19.18x
EV/EBITDA	13.85x
EV/FCF	20.35x
EV/Sales	6.68x
FCF yield	5.79%
Forward P/E	13.5x
P/B ratio	-52.19x
P/E ratio	95.99x
P/S ratio	5.49x
PE Ratio10 Y	39.99x
PE Ratio3 Y	77.83x
PE Ratio5 Y	56.73x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	34.83%
EBITDA Margin	47.62%
FCF margin	31.81%
Gross margin	72.03%
Gross Profit	$34.3B
Gross Profit Growth	11.06%
Gross Profit Growth Q	15.45%
Gross Profit Growth3 Y	3.97%
Gross Profit Growth5 Y	5.95%
Net Income	$2.7B
Net Income Growth	-13.35%
Net Income Growth Q	-45.96%
Net Income Growth Years	0%
Net Income Growth3 Y	-21.86%
Net Income Growth5 Y	-6.73%
Pretax Margin	9.51%
Profit Margin	5.79%
Profit Per Employee	$47,763
Profitable Years	13
ROA	10.03
Roa5y	8.68
ROCE	23.19
Roe5y	1,295.2
ROIC	22.24
Roic5y	22.84

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	19.28%
Cagr1y	10.2%
Cagr3y	14.59%
Cagr5y	15.95%
Div CAGR10	13.15%
Div CAGR3	1.2%
Div CAGR5	6.05%
EPS Growth	-13.24
EPS Growth Q	-45.83
EPS Growth Years	0
EPS Growth3 Y	-21.78
EPS Growth5 Y	-6.98
Revenue Growth	9.5x
Revenue Growth Q	12.43x
Revenue Growth Quarters	6x
Revenue Growth Years	1x
Revenue Growth3 Y	3.45x
Revenue Growth5 Y	4.59x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.46
Assets	$103.3B
Cash	$7.1B
Debt	$55.2B
Debt EBITDA	$2.41
Debt FCF	$3.65
Equity	$-5B
Interest Coverage	7.52
Liabilities	$108.4B
Net Cash	$-48.1B
Net Cash By Market Cap	$-18.41
Net Debt EBITDA	$2.12
Net Debt FCF	$3.18
Tangible Book Value	$-70.5B
Tangible Book Value Per Share	$-39.91
WACC	5.32

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.8
Inventory Turnover	3.67
Net Working Capital	$-7.3B
Quick ratio	0.52
Working Capital	$-6.5B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.04%
Dividend Growth	1.18%
Dividend Growth Years	11%
Dividend per share	$5.02
Dividend Years	14
Dividend Yield	2.5%
Ex Div Date	2026-04-15
Last Dividend	$1.27
Payout Frequency	Quarterly
Payout Ratio	325.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	482.94%
1Y total return	10.19%
200-day SMA	218.6
3Y total return	50.47%
50-day SMA	212.7
50-day SMA vs 200-day SMA	50under200
5Y total return	109.57%
All Time High	244.5
All Time High Change	-17.79%
All Time High Date	2025-10-02
All Time Low	24.42
All Time Low Change	723.03%
All Time Low Date	2013-04-08
ATR	8.04
Beta	0.31
Ch YTD	-12.66
High	207.3
High52	244.5
High52 Date	2025-10-02
High52ch	-17.79%
Low	200
Low52	176.9
Low52 Date	2025-05-15
Low52ch	13.64%
Ma50ch	-5.52%
Price vs 200-day SMA	-8.06%
RSI	41.79
RSI Monthly	51.32
RSI Weekly	42.13
Sharpe ratio	0.34x
Sortino ratio	0.73
Total Return	2.45%
Tr YTD	-11.21
Tr1m	-1.27%
Tr1w	-4.96%
Tr3m	-9.38%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$16.6B
Operating Income Growth	15
Operating Income Growth Q	16.6
Operating Income Growth3 Y	0.7
Operating Income Growth5 Y	5.78
Operating margin	34.83

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,763,680,450%
Shares Insiders	0.07%
Shares Institutions	76.02%
Shares Qo Q	0%
Shares Yo Y	0.04%
Short Ratio	3.15

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$14.4B
Average Volume	12,504.5x
Bv Per Share	-2.85
CAPEX	$-942.1M
Ch10y	284.7
Ch1m	-2.1
Ch1w	-4.96
Ch1y	6.7
Ch3m	-10.14
Ch3y	35.13
Ch5y	73.75
Ch6m	-8.39
Change	-1.95%
Change From Open	-1.23
Close	205
Days Gap	-0.73
Depreciation Amortization	5,966,953,011.5
Dollar Volume	873,948
Earnings Date	2026-04-29
EBIT	$16.6B
EBITDA	$22.7B
EPS	$1.54
F Score	7
FCF	$15.1B
FCF EV Yield	4.91x
Financing CF	-7,987,295,835
Fiscal Year End	December
Founded	2,012
Income Tax	$1.8B
Investing CF	-4,908,851,010
Is Primary Listing	0
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Lynch Fair Value	$10.47
Lynch Upside	-94.79
Ma150	221.3
Ma150ch	-9.17%
Ma20	204.9
Ma20ch	-1.91%
Net CF	3,192,797,880
Open	203.5
P FCF Ratio	17.27
P OCF Ratio	16.26
Payment Date	2026-05-15
Position In Range	13.79
Price Date	2026-05-08
Price EBITDA	$11.54
Relative Volume	0.35x
Revenue	47,573,142,795x
SBC By Revenue	1.57x
Share Based Comp	748,974,645
Tax By Revenue	3.72x
Tax Rate	39.06%
Tr6m	-6.87%
Volume	4,348
Z Score	2.29

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

LON/0QCV dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+2.5%

$5.02 annual per share

Payout ratio

+325.1%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+6.1%

11 consecutive years of growth

Total shareholder yield

+2.5%

Next ex-dividend date: 2026-04-15

Performance

LON/0QCV stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0QCV?

Insider, institutional, and short-interest positioning.

Institutional ownership

+76.0%

Share of float held by funds and institutions

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0QCV momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

41.8

Neutral momentum band

Price vs 200-day MA

-8.1%

50/200-day relationship not available

Beta (5Y)

0.30

Less volatile than the market

Sharpe ratio

0.34

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0QCV

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0QCV stock rating?

lon/0QCV is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0QCV analysis?

The full report lives at /stocks/lon/0QCV/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0QCV?

The latest report frames lon/0QCV around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0QCV page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.